Author

R. Menafra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Organism:human· 2 Assay:whole-exome sequencing· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

B. A. L. M. Deiman· 1 shared C. A. M. v. Bergen· 1 shared D. Cats· 1 shared E. Szczurek· 1 shared H. Mei· 1 shared H. Veelken· 1 shared H.-J. Guchelaar· 1 shared I. Johansson· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

B. A. L. M. Deiman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CACTUS: integrating clonal architecture with genomic clustering and transcriptome profiling of single tumor cells

S. Darvish Shafighi, S. M. Kiełbasa, J. Sepulveda-Yanez, R. Monajemi, D. Cats, H. Mei, R. Menafra, S. Kloet, H. Veelken, C. A. M. v. Bergen, E. Szczurek

CACTUS integrates genomic and transcriptomic data to map single tumor cells to their clonal origins, improving accuracy in follicular lymphoma by combining exome, RNA-seq, and B-cell receptor sequencing.

bioRxiv · Jun 5, 2020Cancer Biology

A unifying model to predict variable drug response for personalised medicine

M. van der Lee, W. G. Allard, R. H. A. M. Vossen, R. F. Baak-Pablo, R. Menafra, B. A. L. M. Deiman, M. J. Deenen, P. Neven, I. Johansson, S. Gastaldello, M. Ingelman-Sundberg, H.-J. Guchelaar, J. J. Swen, S. Y. Anvar

The paper introduces a continuous scale model using full gene sequencing and neural networks to predict CYP2D6 enzyme activity, explaining 79% of interindividual variability in drug response.

bioRxiv · Mar 2, 2020Pharmacology & Toxicology